Butterfly Network, Inc. · NYSE:BFLY
Butterfly Network — Q2 2024 Earnings Presentation
10 slides from Butterfly Network's earnings presentation, Aug 1, 2024
Slide 1: Butterfly Network Q2 2024 Earnings Call
Butterfly Network Q2 2024 Earnings Call August 1, 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequentl
Slide 3: 2024 Strategic Pillars
2024 Strategic Pillars Strengthen Core Expand Differentiate Generate ● Transform standard of ● Continue investing in our ● 2024 Guidance: $75-80mm ● Penetrate further into care through new Ultrasound-on-Chip™ or 15-20% growth Hospitals, Clinic, Veterinary, Med Schools, applications and AI powered too
Slide 4: Transforming Care with the World's First Complete Ultrasound-on-Chip Solution
Transforming Care with the World’s First Complete Ultrasound-on-Chip™ Solution. Q2 2024 Highlights ● Posted Butterfly’s highest quarterly revenue in history. ○ $21.5mm in revenue, reflecting 16% revenue growth YoY, despite it being our toughest comp quarter. ● Achieved $10mm annualized reduction in Op
Slide 5: Unlocking a New Medical School Sales Model
Unlocking a New Medical School Sales Model. 5
Slide 6: 3 new partners announced. Strong inbound continues.
3 new partners announced. Strong inbound continues. 1 new term sheet signed. 5 companies in negotiation concurrently, with 15 total in the pipeline. 6
Slide 7: Update On Supporting Initiatives
Update On Supporting Initiatives. Clinical Research Butterfly iQ+ recognized in the Butterfly filed for revocation of the World Health Organization’s 2024 EU’s Restriction of Hazardous Compendium Substances (RoHS) handheld piezoelectric crystal ultrasound exemption. Access:: https://onlinelibrary.wiley
Slide 8: Record Quarterly Revenue; Improved Full Year Adjusted EBITDA Guidance
Record Quarterly Revenue Improved Full Year Adjusted EBITDA Guidance USD (millions) Q2 2024 Q2 2023*** Change Revenue $21.5 $18.5 16% Gross Margin 58.6% 59.1% (0.5) pts Operating expense $29.8 $42.2 (29%) Adjusted EBITDA Loss* $(8.1) $(17.0) 52% Cash, Cash Equivalents and Marketable Securities** $10
Slide 9: Butterfly March 2024 Investor Day Key Takeaways
Butterfly March 2024 Investor Day Key Takeaways Butterfly Garden and Butterfly has a Butterfly is leading a Powered by Butterfly HomeCare business digital ultrasound will contribute to plan in place, and is revolution with its meaningful revenue actively initiating robust R&D roadmap. generation over the
Slide 10: Thank you! Questions?
Thank you! Questions? 10